Cetirizine does not influence the immune response. 1992

G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
Allergy and Clinical Immunology Service, Department of Internal Medicine Genoa, Italy.

Antihistamines are frequently employed in the treatment of allergic rhinitis and urticaria-angioedema syndrome. We analyzed the in vitro effects of cetirizine on the immune response. To this end the proliferation of peripheral mononuclear cells induced by mitogen and by -CD3, -CD2, or -CD28 monoclonal antibodies has been studied. Since the plasma peak of cetirizine following ingestion of 10 mg is about 1 microgram/mL, the drug was tested in the cultures at the concentration of 0.1, 1, or 10 micrograms/mL. No influence of cetirizine on T cell proliferation was detected. We also evaluated the effect of cetirizine on the expression of the following markers expressed by T cells upon activation: lymphocyte markers ICAM-1, HLA-DR, and CD25 surface expression, alpha-1-acid glycoprotein has been also studied. There was no effect of cetirizine on the investigated immunologic parameters; these data acquire clinical relevance when related to previous reports showing a depression of the immunologic response exerted by other compounds such as ketotifen and theophylline and when related to the recent data about the modulation of ICAM-1 expression on eosinophils by cetirizine. Cetirizine does not affect ICAM-1 expression of lymphocyte membrane.

UI MeSH Term Description Entries
D007665 Ketotifen A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one,Ketotifen Fumarate,Ketotifene,Ketotiphen,Ketotiphene,Zaditen,Fumarate, Ketotifen
D008297 Male Males
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D009961 Orosomucoid Acid Seromucoid,Seromucoid,Serum Sialomucin,alpha 1-Acid Glycoprotein,alpha 1-Acid Seromucoid,A(1)-Acid Seromucoid,Acid alpha 1-Glycoprotein,Alpha(1)-Acid Glycoprotein,alpha 1-Acid Glycoprotein (Acute Phase),alpha 1-Glycoprotein Acid,Acid alpha 1 Glycoprotein,Glycoprotein, alpha 1-Acid,Seromucoid, Acid,Seromucoid, alpha 1-Acid,Sialomucin, Serum,alpha 1 Acid Glycoprotein,alpha 1 Acid Seromucoid,alpha 1 Glycoprotein Acid
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006684 HLA-DR Antigens A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS. HLA-DR,Antigens, HLA-DR,HLA DR Antigens

Related Publications

G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
January 1978, Archives roumaines de pathologie experimentales et de microbiologie,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
January 2013, La Clinica terapeutica,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
October 2013, Immunology,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
April 2023, JCI insight,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
July 1994, Surgery,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
January 1990, Cytokine,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
October 2001, Clinical immunology (Orlando, Fla.),
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
June 2017, Anticancer research,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
January 2020, Reproductive biomedicine online,
G W Canonica, and G Pesce, and S Ruffoni, and S Buscaglia, and F Boero, and G Jing, and J P Rihoux, and G Ciprandi
June 2023, Infectious diseases (London, England),
Copied contents to your clipboard!